Novo Nordisk

Are CagriSema's REDEFINE-2 trial results concerning? Perhaps not

11/03/25 -"Novo’s investors appeared worried yesterday after its promising obesity/diabetes drug candidate, CagriSema’s, another late-stage trial results yielded weight-loss efficacy which was ..."

PDF page sample
Pages
74
Language
English
Published on
11/03/25
Download
You may also be interested by these reports :
17/03/25
Virbac’s 2024 operating profitability was somewhat ahead of the street’s expectations, backed by favourable prices, higher volumes and an improved ...
12/03/25
Roche and Zealand Pharma have agreed to co-develop and co-commercialise Zealand’s phase II weight-loss drug candidate, petrelintide, as monotherapy ...
11/03/25
Vague outlook and slight miss on topline might offer weakness to further build up a position
05/03/25
Worth building a position ahead of results at current price

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO